March 2023

In This Issue/Research Watch/News in Brief
Published in issue: March 2023
p245-248

From the IASLC Tobacco Control Committee
Published in issue: March 2023
p249-253

Editorials

An Individualized Approach to Comorbidities in Lung Cancer
• Malene S. Frank,
• Uffe Bodtger
Published in issue: March 2023
p254-256
Plasma Biomarkers to Monitor Bronchopulmonary Carcinoids—Are We There Yet?
• Anja C. Roden,
• Julian R. Molina
Published in issue: March 2023
p257-259
Two’s Company, Three’s a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity
• Lamis Yehia,
• Maria Laura Centomo,
• Pier Paolo Pandolfi,
• Charis Eng
Published in issue: March 2023
p260-261
Stage I Stereotactic Body Radiation Therapy Outcome’s Prediction Models: Perfection Is the Enemy of Utility
• Sara Ramella,
• Paolo Soda
Published in issue: March 2023
p262-264

Controversies in Thoracic Oncology

Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor
• Melina E. Marmarelis,
• Lova Sun,
• Charu Aggarwal
Published in issue: March 2023
p265-267
In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50%
• Nicolas Girard
Published in issue: March 2023
p268-270

Editorial: Lung Cancer Worldwide

Lung Cancer in the Czech Republic
• Simona Borilova,
• Ladislav Dusek,
• Lenka Jakubikova,
• ...
• Ondrej Bilek,
• Norbert Pauk,
• Marek Svoboda
Published in issue: March 2023
p271-277

Review Articles

Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group
• Sharyn I. Katz,
• Christopher M. Straus,
• Leonid Roshkovan,
• ...
• Victor H. Gerbaudo,
• Roslyn J. Francis,
• Samuel G. Armato III
Published online: December 19, 2022
p278-298
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review
• Conrad B. Falkson,
• Emily T. Vella,
• Peter M. Ellis,
• Donna E. Maziak,
• Yee C. Ung,
• Edward Yu
Published online: November 04, 2022
p299-312

Original Articles

Translational Oncology


Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium
• Miguel García-Pardo,
• Amy Chang,
• Sabine Schmid,
• ...
• Wei Xu,
• Rayjean J. Hung,
• Geoffrey Liu
Published online: November 14, 2022
p313-323

PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion
• Letian Zhang,
• Xiang Zhu,
• Congrong Liu,
• ...
• Xiaojing Zhang,
• Yanqing Wang,
• David W. Goodrich
Published online: December 03, 2022
p324-338
Open Access

Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
• Sarah J. Gao,
• Lan Jin,
• Hugh W. Meadows,
• ...
• Raymond H. Mak,
• Roy H. Decker,
• Benjamin H. Kann
Published online: November 14, 2022
p339-349

Small Cell Lung Cancer


An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
• Kristen Fousek,
• Lucas A. Horn,
• Haiyan Qin,
• ...
• Anish Thomas,
• Jeffrey Schlom,
• Claudia Palena
Published online: November 18, 2022
p350-368
Open Access

Brief Report

Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report
• Benjamin Nisman,
• Kira Oleinikov,
• Hovav Nechushtan,
• ...
• Tamar Peretz,
• Amichay Meirovitz,
• Simona Grozinsky-Glasberg
Published online: December 08, 2022
p369-376

Letters to the Editor

Gene-Gene Interaction in Ever Smokers With Lung Cancer: Is There Confounding by Chronic Obstructive Pulmonary Disease in Genome-Wide Association Studies?
• Robert P. Young,
• Raewyn J. Scott
Published in issue: March 2023
e23-e24

Reply to Scott et al: “Gene-Gene interaction in ever-smokers with lung cancer: Is there confounding by COPD in GWAS?”
• Ruyang Zhang,
• Yi Li,
• Feng Chen,
• David C. Christiani
Published in issue: March 2023
e24-e26

Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib
• Binghao Zhao,
• Jiaming Wu,
• Wenbin Ma
Published in issue: March 2023
e26-e27

Reply to the Letter to the Editor From Zhao et al
• Ibiayi Dagogo-Jack,
• Stan Krulewicz,
• Beow Y. Yeap
Published in issue: March 2023
e27-e28

Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
• Edyta Maria Urbanska,
• Jens Benn Sørensen,
• Eric Santoni-Rugiu
Published in issue: March 2023
e28-e29

Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
• Sai-Hong Ignatius Ou,
• Edward S. Kim
Published in issue: March 2023
e30-e31

Frontmatter

Editorial Board
Published in issue: March 2023
A1-A2
Board of Directors
Published in issue: March 2023
A5
Meeting Announcements
Published in issue: March 2023
A6
Table of Contents
Published in issue: March 2023
A9-A10